华东医药(000963.SZ)：瑞玛比嗪注射液收到药品注册证书

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Sino-American Huadong Pharmaceutical Co., has received approval from the National Medical Products Administration (NMPA) for the marketing authorization of Relmapirazin Injection, a new Class 1 chemical drug aimed at assessing kidney function through non-invasive monitoring [1] Group 1 - The approved product, Relmapirazin Injection, is a non-radioactive, non-iodinated fluorescent GFR tracer [1] - Relmapirazin Injection is designed to be used in conjunction with MediBeacon Inc.'s transdermal glomerular filtration rate measurement device (TGFR) [1] - The combination of Relmapirazin Injection and TGFR aims to evaluate the glomerular filtration rate (GFR) in patients with impaired or normal kidney function through the monitoring of the fluorescence of the exogenous tracer over time [1]